Akanda Corp (AKAN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Akanda Corp stock (AKAN) is currently trading at $0.80. Akanda Corp PE ratio is 0.01. Akanda Corp PS ratio (Price-to-Sales) is 1.94. WallStSmart rates AKAN as Sell.
- AKAN PE ratio analysis and historical PE chart
- AKAN PS ratio (Price-to-Sales) history and trend
- AKAN intrinsic value — DCF, Graham Number, EPV models
- AKAN stock price prediction 2025 2026 2027 2028 2029 2030
- AKAN fair value vs current price
- AKAN insider transactions and insider buying
- Is AKAN undervalued or overvalued?
- Akanda Corp financial analysis — revenue, earnings, cash flow
- AKAN Piotroski F-Score and Altman Z-Score
- AKAN analyst price target and Smart Rating
Akanda Corp
📊 No data available
Try selecting a different time range
AKAN Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Akanda Corp (AKAN)
AKAN trades at a significant discount to its Graham intrinsic value of $1052.91, offering a 100% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Akanda Corp (AKAN) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Akanda Corp (AKAN) Key Strengths (3)
Trading below book value, meaning the market prices it less than net assets
Paying $1.94 for every $1 of annual revenue
Strong revenue growth at 21.90% annually
Supporting Valuation Data
Akanda Corp (AKAN) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very low institutional interest at 2.27%
Micro-cap company with very limited liquidity and high volatility
Akanda Corp (AKAN) Detailed Analysis Report
Overall Assessment
This company scores 34/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 8.7/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Price/Sales, Revenue Growth. Valuation metrics including Price/Sales (1.94), Price/Book (0.49) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 21.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Profitability pressure is visible in Return on Equity at -60.90%, Operating Margin at -443.80%, Profit Margin at -266.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -60.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 21.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AKAN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AKAN's Price-to-Sales ratio of 1.94x trades at a deep discount to its historical average of 22.42x (43th percentile). The current valuation is 100% below its historical high of 454.98x set in Mar 2022, and 1844% above its historical low of 0.1x in Apr 2024. Over the past 12 months, the PS ratio has compressed from ~3.6x as trailing revenue scaled faster than the stock price.
Compare AKAN with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Akanda Corp (AKAN) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Akanda Corp is a strong growth company balancing expansion with improving profitability. Revenue reached 836,660 with 22% growth year-over-year. The company is currently unprofitable, posting a -266.3% profit margin.
Key Findings
The company is unprofitable with a -266.3% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -375,608, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Akanda Corp maintain 22%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.69, so expect amplified moves relative to the broader market.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Akanda Corp.
Bottom Line
Akanda Corp offers an attractive blend of growth (22% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Akanda Corp(AKAN)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Akanda Corporation. The company is headquartered in New Romney, the United Kingdom.